A Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of Volociximab (M200) in Combination With Carboplatin and Paclitaxel in Subjects With Previously Untreated Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of Volociximab (M200) in Combination With Carboplatin and Paclitaxel in Subjects With Previously Untreated Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Carboplatin; Paclitaxel; Volociximab
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Apr 2012 Abbott Laboratories added as trial sponsor, lead trial centre and actual patients number (33) as reported by ClinicalTrials.gov.
    • 15 Sep 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 15 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top